News

Overall Survival Advantage Eludes Afatinib in NSCLC


 

Dr. Miller has received honoraria for consulting and other support from Boehringer-Ingelheim, the study sponsor, as well as from Genentech, Pfizer, and Roche. Several coinvestigators have financial relationships including employment with Boehringer-Ingelheim. Prof. Soria receives consultancy fees from several companies including Boehringer-Ingelheim.

Pages

Recommended Reading

Melanonychia Striata Warrants Biopsy in Most Cases
MDedge Internal Medicine
Chronic Lymphocytic Leukemia Patients Predisposed to Aggressive Melanoma
MDedge Internal Medicine
Large Thyroid Nodules Linked to High Malignancy Risk
MDedge Internal Medicine
Type 2 Diabetes Linked to Higher Risk for Colorectal Adenomas
MDedge Internal Medicine
FDA Panel Does Not Recommend Dosing Change for Aranesp
MDedge Internal Medicine
Basal Thyroglobulin Values Guide Intensity of Thyroid Cancer Follow-Up
MDedge Internal Medicine
Cetuximab Trial Points Toward Targeting EGFR in Triple-Negative Breast Cancer
MDedge Internal Medicine
WHI: HT Raises Long-Term Breast Cancer Incidence, Disease Stage, and Mortality
MDedge Internal Medicine
In the Pipeline: Figitumumab Active in Refractory Ewing's Sarcoma
MDedge Internal Medicine
Targeting Met Delays Progression in Advanced NSCLC
MDedge Internal Medicine